-
公开(公告)号：JP2010022372A
公开(公告)日：2010-02-04
申请号：JP2009205660
申请日：2009-09-07
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08 , G01N33/53
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL (non-Hodgkin lymphoma), repeatedly usable and easily and efficiently producible. SOLUTION: There is provided an antibody containing at least one CDR (Complementarity Determining Region) derived from a mouse monoclonal antibody having specificity for CD22. Also provided is a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further provided are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and use of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation: 要解决的问题：提供用于治疗NHL（非霍奇金淋巴瘤）的抗体分子，可重复使用且容易且高效地生产。 解决方案：提供了含有至少一种衍生自对CD22具有特异性的小鼠单克隆抗体的CDR（互补决定区）的抗体。 还提供了CDR移植抗体，其中至少一个CDR是修饰的CDR。 还提供了编码抗体分子链，载体，转化的宿主细胞的链DNA序列和抗体分子在治疗由表达CD22的细胞介导的疾病中的用途。 版权所有（C）2010，JPO＆INPIT
-
公开(公告)号：JP2013252147A
公开(公告)日：2013-12-19
申请号：JP2013185920
申请日：2013-09-09
Applicant: UCB PHARMA SA
Inventor： RAPECKI STEPHEN EDWARD , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C12N15/09 , A61K39/395 , A61K45/00 , A61K47/34 , A61K47/48 , A61P11/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
Abstract: PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity to an antigenic determinant of IL-17, to provide a therapeutic use of the antibody molecule, and to provide a method for forming the antibody molecule.SOLUTION: A neutralizing antibody including a heavy chain and binding to human IL-17 is regulated so that the variable domain of the heavy chain may contain at least one of a CDR having a sequence represented by SEQ ID NO: 1 as the CDR-H1, a CDR having a sequence represented by SEQ ID NO: 2 as the CDR-H2, and a CDR having a sequence represented by SEQ ID NO: 3 as the CDR-H3.
-
公开(公告)号：JP2010246553A
公开(公告)日：2010-11-04
申请号：JP2010128372
申请日：2010-06-04
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P9/10 , A61P17/00 , A61P19/02 , A61P19/10 , A61P25/02 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07K16/24 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/08
CPC classification number: C07K16/245 , A61K47/60 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
Abstract: PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity for the antigenic determinant of IL-1β; to provide therapeutic use of the antibody molecule; and to provide a method for producing the antibody molecule. SOLUTION: There are provided: the neutralizing antibody having specificity for human IL-1β comprising a heavy chain, wherein the variable domain of the heavy chain comprises at least one of CDR having individually a specific amino acid sequence as CDR-H1, H2 or H3; a method of production thereof; and pharmaceutical compositions containing the antibody. COPYRIGHT: (C)2011,JPO&INPIT
Abstract translation: 要解决的问题：提供对IL-1β的抗原决定簇具有特异性的抗体分子; 以提供抗体分子的治疗用途; 并提供生产抗体分子的方法。 提供：中和抗体对包含重链的人IL-1β具有特异性，其中重链的可变结构域包含具有单独特异性氨基酸序列作为CDR-H1的至少一个CDR， H2或H3; 其生产方法; 和含有抗体的药物组合物。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：JP2010207241A
公开(公告)日：2010-09-24
申请号：JP2010116444
申请日：2010-05-20
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
Inventor： POPPLEWELL ANDREW GEORGE
IPC: C12N15/09 , C07K16/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/72 , C12P21/02 , C12P21/08
CPC classification number: C07K16/2875 , C07K16/00 , C07K2317/55 , C12N15/72
Abstract: PROBLEM TO BE SOLVED: To provide a dicistronic message using variable intergenic sequences.
SOLUTION: The dicistronic message for producing antibodies including an upstream side cistron containing a DNA encoding either heavy chains or light chains of a particular antibody molecule and a down stream cistron containing a DNA encoding either light chains or heavy chains corresponding thereto and having specific antigen binding specificity is provided. In the dicistronic message, the two cistrons are linked by an optimized intergenic sequence.
COPYRIGHT: (C)2010,JPO&INPITAbstract translation: 要解决的问题：提供使用可变基因间序列的分歧信息。 解决方案：用于产生抗体的双顺反子信息，包括含有编码特定抗体分子的重链或轻链的DNA的上游侧顺反子和含有编码与其对应的轻链或重链的DNA的下游顺反子，并具有 提供特异性抗原结合特异性。 在双顺反子信息中，两个顺反子通过优化的基因间序列相连。 版权所有（C）2010，JPO＆INPIT
-
公开(公告)号：JP2009108086A
公开(公告)日：2009-05-21
申请号：JP2008294819
申请日：2008-11-18
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P9/00 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules containing at least one CDR obtained from a mouse monoclonal antibody having specificity for human KDR. SOLUTION: A CDR grafted antibody in which at least one of the CDRs is a hybrid CDR is disclosed. Also DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases, in which VEGF and/or KDR are implicated, are disclosed. COPYRIGHT: (C)2009,JPO&INPIT
Abstract translation: 待解决的问题：提供含有至少一种CDR的抗体分子，其获自具有对人KDR特异性的小鼠单克隆抗体。 解决方案：公开了其中至少一个CDR是杂交CDR的CDR移植抗体。 还公开了编码抗体分子链，载体，转化的宿主细胞的DNA序列和抗体分子在其中涉及VEGF和/或KDR的疾病的治疗中的用途。 版权所有（C）2009，JPO＆INPIT
-
Patent Agency Ranking
公开(公告)号：JP2013230158A
公开(公告)日：2013-11-14
申请号：JP2013140245
申请日：2013-07-04
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K31/7088 , A61K38/16 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL, capable of being repeatedly used and easily and efficiently produced.SOLUTION: An antibody containing at least one CDR obtained from a mouse monoclonal antibody having specificity to CD22 is disclosed. A CDR transplanted antibody, wherein at least one CDR is a modified CDR, is also disclosed. Furthermore, a DNA sequence encoding chains of antibody molecules, a vector, transformed host cells and use of the antibody molecules in the treatment of diseases mediated with CD22 expressing cells are disclosed.
Abstract translation: 要解决的问题：提供用于治疗NHL的抗体分子，能够重复使用并且容易且有效地产生。解决方案：公开了含有至少一种CDR的抗体，其具有对CD22特异性的小鼠单克隆抗体。 还公开了CDR移植抗体，其中至少一个CDR是经修饰的CDR。 此外，公开了编码抗体分子链，载体，转化的宿主细胞的DNA序列和抗体分子在用CD22表达细胞介导的疾病的治疗中的用途。
-
公开(公告)号：WO2010096418A3
公开(公告)日：2012-06-14
申请号：PCT/US2010024377
申请日：2010-02-17
Applicant: UCB PHARMA SA , LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEPHEN GRAHAM , SHPEKTOR DIANA , ZHANG YI
Inventor： LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEPHEN GRAHAM , SHPEKTOR DIANA , ZHANG YI
IPC: C07K16/28 , A61K39/395 , C07K16/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
8.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 审中-公开结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途
公开(公告)号：WO2008118356A3
公开(公告)日：2008-11-20
申请号：PCT/US2008003735
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA , BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。
-
公开(公告)号：WO2008047134A3
公开(公告)日：2008-06-12
申请号：PCT/GB2007003983
申请日：2007-10-18
Applicant: UCB PHARMA SA , ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD
Inventor： ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD
IPC: C07K16/24 , A61K39/395 , A61P35/00 , A61P37/06 , C12N15/13
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。
-
公开(公告)号：EP2398498A4
公开(公告)日：2013-05-01
申请号：EP10744211
申请日：2010-02-17
Applicant: UCB PHARMA SA
Inventor： LAWSON ALASTAIR DAVID GRIFFITHS , NESBITT ANDREW MALCOLM , POPPLEWELL ANDREW GEORGE , SHAW STEPHEN GRAHAM , SHPEKTOR DIANA , ZHANG YI
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
-
-
-
-
-
-
-
-
Search Results
161
records
(took 0.029 seconds)
